Therapist Unlimited Blog

Drinking too much liquor might be bad for the health but for some instances it is not that harmful.
A recent medical study has shown that drunk patients have better chances of surviving trauma injuries than their sober counterparts.
According to the report, trauma patients who were intoxicated before their injuries were more likely to survive than trauma patients who suffered similar injuries but were sober at
the time.
To get the result, researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) surveyed 7,985 trauma patients of similar age and with similar injuries to determine if the consumption of alcohol prior to injury affected
outcome.
Based on their study they discovered that 7 percent of the sober patients died compared to just 1 percent of the patients who had been drinking.

Getting drunk is not that all bad after-all.

"This study is not encouraging the use of alcohol," said Christian de Virgilio, MD, LA BioMed’s principal investigator for the study. "It is seeking to
further explore earlier studies that had found alcohol may improve the body’s response to severe injuries. If alcohol is proven to improve the body’s
response to traumatic injury, it could lead to treatments that help patients survive and recover more quickly."
Alcohol consumption is already known to be one of the leading causes of accident and injury, with a previous study finding it contributes to about
one-third of all trauma-related deaths. Previous studies found trauma patients who had abused alcohol for a long period of time had lower survival rates.
But recent studies also found alcohol consumption may protect against death by changing the chemical response to injury.
"This study adds further support to the possibility that alcohol could be altering the body’s response to injury in a way that helps ensure survival," said
Dr. de Virgilio. "Given these findings, more research is needed to determine if there is some role for alcohol in the management of trauma patients.

The American Academy of Child and Adolescent Psychiatry (AACAP) is a medical professional membership association representing the majority of child and adolescent psychiatrists in the United States.
Established in 1953, the AACAP is the leading national medical association dedicated to the advancement of medical contributions to the knowledge, diagnosis and treatment for the estimated 7—12 million American youth under 18 years of age who are affected by emotional, behavioral, developmental and mental disorders.
In addition to providing print resources to mental health professionals and the general public, the AACAP also works with government agencies and mental health groups to improve mental health care and influence public policy.
The Academy publishes the Journal of the American Academy of Child and Adolescent Psychiatry monthly.

Federal Advocacy
 

Despite treatment advances and better early identification, most youth with mental illnesses do not receive treatment. Some of the barriers to treatment include: a sever shortage of child and adolescent psychiatrists, lack of adequate coverage of services within health care systems, lack of research funding, lack of community mental health services. The AACAP has a legislative agenda to help eliminate these barriers.

Member Benefits
 

The Journal of the American Academy of Child and Adolescent Psychiatry by far the most prestigious in its field, the monthly Journal is a primary source for the latest research and studies in child and adolescent psychiatry.
Members also have access to the complete Journal online archive as well as articles published online ahead of print.
 

To learn more about the organization you can visit their official website at http://www.aacap.org/.

Who says drinking too much coffee is bad for the health?
A recent medical study has shown that patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers.
Based on the research made by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI) it was discovered that that patients with hepatitis C-related bridging fibrosis or cirrhosis who did not respond to standard disease treatment benefited from increased coffee intake.
Freedman explained an effect on liver disease was not observed in patients who drank black or green tea.
It is said that hepatitis C virus (HCV) infects approximately 2.2% of the world’s population with more than 3 million Americans infected. The Centers for Disease Control and Prevention (CDC) cites HCV as the leading cause of liver transplantation in the U.S. and accounts for 8,000 to 10,000 deaths in the country annually. Globally, the World Health Organization (WHO) estimates 3 to 4 million persons contract HCV each year with 70% becoming chronic cases that can lead to cirrhosis of the liver and liver cancer.
This study included 766 participants enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C-related bridging fibrosis or cirrhosis and failed to respond to standard treatment of the anti-viral drugs peginterferon and ribavirin.

It is time to drink coffee for chronic hepatitis C patients.

At the onset of the study, HALT-C patients were asked to report their typical frequency of coffee intake and portion size over the past year, using 9 frequency categories ranging from ‘never’ to ‘every day’ and 4 categories of portion size (1 cup, 2 cups, 3-4 cups, and 5+ cups). A similar question was asked for black and green tea intake. "This study is the first to address the association between liver disease progression related to hepatitis C and coffee intake," stated Freedman.
Participants were seen every 3 months during the 3.8-year study period to assess clinical outcomes which included: ascites (abnormal accumulation of fluid in the abdomen), prognosis of chronic liver disease, death related to liver disease, hepatic encephalopathy (brain and nervous system damage), hepatocellular carcinoma (liver cancer), spontaneous bacterial peritonitis, variceal hemorrhage, or increase in fibrosis. Liver biopsies were also taken at 1.5 and 3.5 five years to determine the progression of liver disease.
Results showed that participants who drank 3 or more cups of coffee per day had a relative risk of .47 for reaching one of the clinical outcomes. Researchers did not observe any association between tea intake and liver disease progression, though tea consumption was low in the study. "Given the large number of people affected by HCV it is important to identify modifiable risk factors associated with the progression of liver disease," said Freedman. "Although we cannot rule out a possible role for other factors that go along with drinking coffee, results from our study suggest that patients with high coffee intake had a lower risk of disease progression."

Those persons suffering from rhinosinusitis has a high tendency to also suffer from depression due to their medical condition.
This was the result of a new study conducted on 73 patients wherein some 9.6 percent of these people suffered depression due to their condition.
The research also showed that 20.5 percent scored in the range of a major depressive disorder using an objective screening instrument with high sensitivity and specificity for diagnosing depression, the Patient Health Questionnaire-9.
Additionally, the disease-specific and general health-related quality of life (QOL) in these patients was worse than those who did not exhibit signs of depression.

Patients inflicted with rhinosinusitis better be careful since their medical condition could also result in depression.

Patients with depression and CRS scored significantly worse in most QOL measures, including bodily pain, and physical and social functioning. The authors believe this casts particular light on the impact of depression on diseases of the head and neck, which is to this point little is understood.
They contend that if physicians are to optimize their patients’ health, screening for both CRS and depression is warranted.

It is time to cheer up for colon cancer patients around the world.
Immunology experts in the US and China have discovered human stem cells that "fool" the immune system may provide a vaccination for colon cancer.
The study was led by Dr. Bei Liu and Dr. Zihai Li in collaboration with stem cell expert Dr. Renhe Xu at the University of Connecticut Stem Cell Institute and is to be published in the journal Stem Cells.
The study builds on an old notion that immunizing with embryonic materials might produce anti-tumor responses, but this has only been shown in animal studies.
However, this new groundbreaking study showed for the first time that that human embryonic stem (hES) cells injected into mice produced a consistent immune response against colon cancer cells, opening a new door for cancer vaccine research.
Long before embryonic stem cells were used for genetic and developmental studies, scientists understood that they shared similar properties with cancer cells, especially in the way they form and replicate.
Immune systems recognize antigens like proteins on the surface of tumor cells that can trigger an immune response to make antibodies to fight the tumor.

Stem cells could soon provide vaccine to fight colon cancer among humans.

However, most of the current research on cancer vaccines target these antigens, while this study takes a different approach: what if you used stem cells into fooling the host immune system into thinking there was cancer present and trigger a tumor fighting response that way? That would open a new route to using stem cells to make a universal cell-based vaccine against cancer.
For the study the researchers vaccinated laboratory mice with human embryonic stem (hES) cells and saw a dramatic decline in tumor growth in the immunized mice.
This showed that immunized mice could generate a strong anti-tumour response through the application of hES cells.
The researchers also found that while natural hES cells triggered a strong anti-tumour response, artificially induced pluripotent stem cells (iPSC) did not.
This is a significant discovery because it challenges the idea recently put forward in a number of studies that iPSC have the potential to replace hES cells at the forefront of stem cell research.
Liu said:"Although we have only tested the protection against colon cancer, we believe that stem cells might be useful for generating an immune response against a broad spectrum of cancers, thus serving as a universal cancer vaccine."

A recent medical study has shown that a great number of prostate patients do not anymore need treatment for their medical condition.
In the largest study of its kind, the international team of pathologists studied an initial 4,000 prostate cancer patients over a period of 15 years to further understanding into the natural progression of the disease and how it should be managed.
The research could be used to develop a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.
Globally, prostate cancer is the fifth most common malignancy and accounts for 13% of male deaths in the UK. Studies have shown that men with non-aggressive prostate cancer can live with the disease untreated for many years, but aggressive cancer requires immediate treatment.
Pathologists found that the presence of a protein, called Hsp-27, in cancer cells was an indicator that the disease will progress and require treatment. The study showed, however, that in more than 60% of cases the protein was not expressed and the cancer could be managed by careful monitoring, rather than with active invention methods, such as drug treatment or surgery.
The protein normally has a positive function in the body, helping healthy cells survive when they are placed under ’stressful’ conditions, such as disease or injury. If the protein is expressed in cancer, however, it can prevent the diseased cells from dying, allowing the cancer to progress. The team, supported by Cancer Research UK (CRUK) and in collaboration with scientists in London and New York, found that the protein can be used to predict how the disease will behave and could help doctors advise patients on how the disease could affect their daily lives.

A recent study has shown that prostate cancer do not necessarily need medical treatment.

Professor Chris Foster, Head of the University’s Division of Pathology, explains: "Cancer of any kind is a very distressing disease and has the ability to impact on every aspect of a person’s life. Chemotherapy and surgery can also have a significant effect on health and wellbeing and that is why it is important that we first understand the biological nature of the disease and how it will behave in each individual patient, before determining if and when a person needs a particular type of treatment.
"By studying the disease in a large number of men throughout the UK and over a long period of time, we have been able to get a more complete picture of how to manage the disease successfully, while limiting the negative impact it can have on a patient’s life. The study also demonstrates the role of modern of Pathology, not only in establishing diagnoses but in determining if the subsequent management of individual patients is biologically appropriate for their particular condition.
"The protein  or biomarker we have identified provides us with a signal that the disease will continue to progress. We know that at the point this marker is expressed, medics need to administer treatment to kill the cancer cells. We have shown that in the majority of cases, however, this marker is not expressed and therefore patients do not necessarily need to go through treatment to lead a normal life."

Cancer patients better avoid getting depressed since doing so could reduce their chances of survival.
A recent medical study has found out that there is a need for systematic screening of psychological distress and subsequent treatments to ensure proper treatment for cancer patients.
To get the data they are looking for, graduate student Jillian Satin, MA, of the University of British Columbia in Vancouver, Canada, and her colleagues analyzed a total of 9417 patients and examined the effects of depression on patients’ cancer progression and survival.
Based on the study they made they discovered that an increased risk of death in patients who report more depressive symptoms than others and also in patients who have been diagnosed with a depressive disorder compared to patients who have not.
 

Cancer patients need to avoid getting depressed if they wish to be treated of their medical condition.

Satin revealed in the combined studies, the death rates were up to 25 percent higher in patients xperiencing depressive symptoms and 39 percent higher in patients diagnosed with major or minor depression.
Satin added the increased risks remained even after considering patients’ other clinical characteristics that might affect survival, indicating that depression may actually play a part in shortening survival.
Despite their findings, the researchers admitted additional research needs to be conducted before any conclusions can be reached.
The researchers explained their analysis combined results across different tumor types, so future studies should look at the effects of depression on different kinds of cancer.
Moreover, the researchers noted that the actual risk of death associated with depression in cancer patients is still small, so patients should not feel that they must maintain a positive attitude to beat their disease.
The researchers said their study indicates that it is important for physicians to regularly screen cancer patients for depression and to provide appropriate treatments.

Here is a piece of good news to all those patients suffering from heart failure.
A recent research has shown that a therapy called cardiac resynchronization can significantly delay the progression of heart failure.
Based on the research the treatment reduced the risk of serious heart failure events by 41 percent.
Dr. David Wilber, a co-author of the study and director of the Cardiovascular Institute at Loyola University Chicago
Stritch School of Medicine revealed the research has shown that for the first time, the onset of heart failure symptoms and hospitalization for heart failure can be delayed with pacing therapy.
According to researchers, a device implanted in the upper chest delivers electrical impulses that help synchronize contractions of the left ventricle, the heart’s main pumping chamber.
Some 1,820 patients from 110 centers in the United States, Canada and Europe participated in the study.
The researchers revealed all patients in the trial had been diagnosed with early stage, mild heart failure (Class 1 and Class 2 on the New York Heart Association classification system).
The study’s principle investigator is Dr. Arthur Moss of the University of Rochester
Medical Center.
Patients were randomly assigned to two groups. A control group received an implanted defibrillator, and a second group received a defibrillator plus cardiac resychronization. (A defibrillator is a device that shocks the heart back to a normal rhythm if the patient experiences a life-threatening irregular heartbeat.)

Those persons suffering from heart failure can now use cardiac resynchronization as treatment for their medical condition.
 

Compared with the control group, the cardiac resychronization group had a significantly improved heart-pumping efficiency and a 41 percent lower risk of heart-failure events that required hospitalization or outpatient treatment with intravenous drugs.
Loyola heart failure patient Rosemary Jakubowski of Elmwood Park, Il. said that before she received cardiac resychronization, she had experienced significant fatigue.
Since receiving cardiac resychronization, Jakubowski has been taking kickboxing and swim aerobics classes, without fatigue.
The Food and Drug Administration has approved cardiac resychronization for patients with Class 3 (moderate) and Class 4 (severe) heart failure. Such patients experience marked limitations in physical activity or are unable to do any physical activity at all without discomfort.
Wilber said the study has shown that certain patients with early-stage, mild heart failure also can benefit from cardiac resychronization.

 

A recent study has shown that the feelings of depression could be one reason patients fail to follow their doctors’ orders on exercising and eventually become less physically active.
It is said that although past research shows that exercise improves chronic health conditions, such as heart disease and diabetes, it also shows that patients with these conditions often suffer from depression.
To get the result, the researchers evaluated 11 studies comprising some 20,000 patients.
Based on eight studies reported that having symptoms of depression after a coronary event, such as heart attack, was a significant risk factor for developing a sedentary lifestyle or a poor adherence to an exercise regimen recommended by the patients’ doctor.

Those patients who are less active could be suffering from depression.

Babak Roshanaei-Moghaddam, M.D. of the department of psychiatry and behavioral sciences at University of Washington in Seattle and lead author of the study explained there are both behavioral habits associated with depression, such as smoking and obesity, which may then limit exercise motivation and enjoyment, as well as biologic factors that can cause obesity and decrease energy level, exercise tolerance and pain threshold.
Evette Joy Ludman, Ph.D., of Seattle-based Group Health Cooperative, who had no affiliation with the study, for her part said depression can indeed make people have less motivation and energy to exercise.
Ludman added the physical activity is not only important for preventing and managing many chronic conditions; it can be very helpful for improving mood and other symptoms of depression.

Patients suffering from leukemia better start doing any form of exercise now.
This developed after a recent study has shown that doing some exercise offers benefits to people suffering from leukemia.
According to the research made by the University of North Carolina at Chapel Hill indicates that exercise may be a great way to do just that, combating the debilitating fatigue that these patients experience.
Based on the research it was discovered that physical activity can significantly improve symptoms of fatigue and depression, increase cardiovascular endurance and maintain quality of life for adult patients undergoing treatment for leukemia.
To get the data, 10 patients participated in the EQUAL (Exercise and Quality of Life in Leukemia/ Lymphoma Patients) study.

To feel better leukemia patients could do some form of exercise as a form of therapy for their medical condition.

Each patient was provided with specially-treated exercise equipment to minimize the risk of infection.
They participated in an individualized exercise session while in the hospital for the 3-5 weeks of the induction phase of leukemia treatment.
The exercise prescription comprised of aerobic and resistance exercises, core exercises, and light stretches tailored to the patient’s level of fitness and leukemia symptoms. Upon their discharge from the hospital, each patient received an aerobic- based exercise prescription to use during their 2-week home recovery period.
Claudio Battaglini, Ph.D., assistant professor of exercise and sport science and UNC Lineberger member revealed in their study they found that the patients experienced significant reduction in total fatigue and depression scores, as well as improved
cardiorespiratory endurance and maintenance of muscular endurance.
Battaglini added their study is important because of the numerous side-effects related to cancer treatment, and particularly leukemia treatment, which requires confinement to a hospital room for 4-6 weeks to avoid the risk of infection.
He said they have demonstrated that these patients not only can complete an exercise program in the hospital but that they may receive both physiological and psychological benefits that could assist in their recovery.